Leveraging Key Learnings From CLN-978’s Clinical Studies & Regulatory Success to Better Apply Your TCE in Autoimmune Trials
Time: 9:00 am
day: Day Two
Details:
- Reviewing the clinical study design for the T-cell engager, CLN-978, to maximize the efficiency of your clinical development path – investigating where T-cell engagers are best fit in the treatment timeline for the specific modality
- Understanding the patient selection process and applying this a specific disease type: Do we start with healthy volunteers? Which patients benefit from which targets? What are the implications of different jurisdictions of running these trials?
- Investigating the regulatory landscape and hurdles for preclinical and clinical studies with T-cell engagers in autoimmunity, and understanding how CLN-978 were able to overcome this to create a successful dosing schedule with follow up safety
